Evidence map›Paper›PMID 24802609›Full record

SynthesisPloS one2014

Meta-analysis reveals a lack of association between UGT2B17 deletion polymorphism and tumor susceptibility.

Xiaheng Deng, Yidong Cheng, Xiao Yang, Shuang Li, Ruizhe Zhao, Kang Liu, Jinliang Liu, Qiang Cao, Chao Qin, Pengfei Shao and 4 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. A Novel Mechanism to Drive Castration-Resistant Prostate Cancer.Trends in endocrinology and metabolism: TEM · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Xiaheng DengDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yidong ChengDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiao YangDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shuang LiDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ruizhe ZhaoDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kang LiuDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jinliang LiuDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qiang CaoDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chao QinDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pengfei ShaoDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaoxin MengDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie LiDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qiang LuDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Changjun YinDepartment of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUGT2B17 is a vital member of the UGT2 family and functions as a detoxification enzyme which catalyzes the glucuronidation of lipophilic compounds. Accumulating evidences implicates that it may contribute to the susceptibility of tumor risk. Identification of a UGT2B17 deletion polymorphism has attracted studies to evaluate the association between the UGT2B17 deletion polymorphism and tumor risk in diverse populations. However, the available results are conflicting.

methodsA meta-analysis based on 14 studies from 10 publications including 5,732 cases and 5,112 controls was performed. Published literature from PubMed, EMBASE and Web of Science was pooled and the crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the associations.

resultsConclusively, our results indicate that individuals with a UGT2B17 deletion polymorphism were associated with tumor risks (OR = 1.29, 95% CI = 1.03-1.63, P<0.001) in a recessive model. However, after excluding two studies for their heterogeneity, the result then demonstrated that the UGT2B17 deletion polymorphism was not associated with tumor risks (OR = 1.118, 95% CI = 0.938-1.332, P>0.1). A subgroup analysis based on tumor type, sex or race did not show significant results.

conclusionThese results suggest that the UGT2B17 deletion polymorphism is not associated with tumor risks.

Indexed as

Databases, FactualDisease SusceptibilityFemaleGenotypeGlucuronosyltransferaseHumansMaleMinor Histocompatibility AntigensNeoplasmsOdds RatioPolymorphism, GeneticRisk FactorsSequence DeletionGlucuronosyltransferaseMinor Histocompatibility AntigensUGT2B17 protein, human

Identifiers

PMID24802609
PMCPMC4011861
OpenAlexW2087546009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.